Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Bortezomib in Waldenström macroglobulinaemia pts who fail BTKi shows ORR of 88%; at median follow up of 39 mos, median treatment-free survival and overall survival were 18 (95% confidence interval 13-22) and 22 (17-45) mos.”
Title: Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia
Authors: Jahanzaib Khwaja, Nicole Japzon, Simona Gatto, Jindriska Lindsay, Charalampia Kyriakou, Shirley D’Sa
You can read the Full Article on Hematology Reports.
You can find other articles featuring Robert Orlowski on OncoDaily.
